← Leaderboards
Gregg A Dean
Colorado State University
$12,732,502
Attributed
$16,682,762
Total exposure
17
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,682,762 · 17
By mechanism
R01$7,927,427 · 3
T32$4,052,773 · 3
R21$2,443,470 · 5
T34$1,426,438 · 1
K02$288,240 · 1
R38$209,164 · 1
Top collaborators
- Zaid Abdo7 shared
- Rodolphe Barrangou7 shared
- Sandra L Quackenbush4 shared
- Mark D Zabel4 shared
- Kelly S Santangelo3 shared
Most similar at Colorado State University
Same institution · by research overlap
- Zaid Abdo$1,905,191
- Rodolphe Barrangou$1,320,899
- Tracy L Webb$528,562
- Grzegorz Szamel$2,651,286
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseResponseOralFeline Immunodeficiency VirusProgramsProbioticsFlagellinImmunizationMucosal VaccineAntigensVaccinesAdjuvantOrganismRecombinantsMucous MembraneVector VaccineCellsImmunogenicityOral VaccineEngineeringImmunogenicImmunoglobulin AAgonistAffect
Grant awards (55)
Biomedical Research Training for Veterinarians$525,701
T32 · FY2025 · OD
MARC at Colorado State University$478,573
T34 · FY2025 · GM · contact PI
CSU Infectious Disease Research and Response Training Program$378,016
T32 · FY2025 · AI · contact PI
Colorado State University StARR Program in Infectious Disease and Immunology$209,164
R38 · FY2025 · AI · contact PI
CSU Infectious Disease Research and Response Training Program$143,025
T32 · FY2025 · AI · contact PI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$720,054
R01 · FY2024 · AI · contact PI
MARC at Colorado State University$474,840
T34 · FY2024 · GM · contact PI
CSU Infectious Disease Research and Response Training Program$466,724
T32 · FY2024 · AI · contact PI
Biomedical Research Training for Veterinarians$252,447
T32 · FY2024 · OD
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$758,912
R01 · FY2023 · AI · contact PI
Biomedical Research Training for Veterinarians$485,661
T32 · FY2023 · OD
CSU Infectious Disease Research and Response Training Program$465,165
T32 · FY2023 · AI · contact PI
MARC at Colorado State University$316,560
T34 · FY2023 · GM · contact PI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$679,126
R01 · FY2022 · AI · contact PI
CSU Infectious Disease Research and Response Training Program$461,662
T32 · FY2022 · AI · contact PI
MARC at Colorado State University$156,465
T34 · FY2022 · GM · contact PI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$11,389
R01 · FY2022 · AI · contact PI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$681,022
R01 · FY2021 · AI · contact PI
CSU Infectious Disease Research and Response Training Program$214,464
T32 · FY2021 · AI · contact PI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$691,456
R01 · FY2020 · AI · contact PI
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilus$9,137
R01 · FY2020 · AI · contact PI
Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPER$185,875
R21 · FY2015 · AI · contact PI
Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPER$223,050
R21 · FY2014 · AI · contact PI
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1$339,531
R01 · FY2012 · DE · contact PI
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1$330,440
R01 · FY2011 · DE · contact PI
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1$342,961
R01 · FY2010 · DE · contact PI
Basis and modulation of the innate immune defect in FIV$325,592
R01 · FY2010 · AI · contact PI
Comparative Medicine and Translational Research Training Program$271,186
T32 · FY2010 · RR · contact PI
International Feline Retrovirus Research Symposium$27,000
R13 · FY2010 · AI · contact PI
Basis and modulation of the innate immune defect in FIV$390,209
R01 · FY2009 · AI · contact PI
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1$345,940
R01 · FY2009 · DE · contact PI
Comparative Medicine and Translational Research Training Program$259,770
T32 · FY2009 · RR · contact PI
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1$207,368
R01 · FY2009 · DE · contact PI
Optimizing Immunogenicity of Lactobacillus as a Mucosal Vaccine Against HIV-1$185,989
R21 · FY2009 · AI · contact PI
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1$345,263
R01 · FY2008 · DE · contact PI
Basis and modulation of the innate immune defect in FIV$327,777
R01 · FY2008 · AI · contact PI
Optimizing Immunogenicity of Lactobacillus as a Mucosal Vaccine Against HIV-1$222,750
R21 · FY2008 · AI · contact PI
Comparative Medicine and Translational Research Training Program$128,952
T32 · FY2008 · RR · contact PI
Basis and modulation of the innate immune defect in FIV$334,125
R01 · FY2007 · AI · contact PI
In vivo significance of T-reg cells during FIV infection$285,138
R21 · FY2006 · AI · contact PI
In vivo significance of T-reg cells during FIV infection$292,000
R21 · FY2005 · AI
Interacton of HIV with Toll-like Receptors$73,000
R03 · FY2005 · AI
Recombinant Listeria: A Biologic Vaccine Vector For FIV$607,668
R21 · FY2004 · AI
BASIS AND MODULATION OF THE INNATE IMMUNE DEFECT IN FIV$256,375
R01 · FY2004 · AI
Interacton of HIV with Toll-like Receptors$73,000
R03 · FY2004 · AI
BASIS AND MODULATION OF THE INNATE IMMUNE DEFECT IN FIV$256,375
R01 · FY2003 · AI
BASIS AND MODULATION OF THE INNATE IMMUNE DEFECT IN FIV$256,375
R01 · FY2002 · AI
CYTOKINE RESPONSE IN FIV AND SIV IMMUNODEFICIENCY$96,080
K02 · FY2002 · AI
BASIS AND MODULATION OF THE INNATE IMMUNE DEFECT IN FIV$318,000
R01 · FY2001 · AI
RECOMBINANT LISTERIA--BIOLOGIC VACCINE VECTOR FOR FIV$220,500
R21 · FY2001 · AI
CYTOKINE RESPONSE IN FIV AND SIV IMMUNODEFICIENCY$96,080
K02 · FY2001 · AI
CHARACTERIZATION/MODULATION OF CYTOKINE RESPONSES IN FIV$81,125
R29 · FY2001 · AI
RECOMBINANT LISTERIA--BIOLOGIC VACCINE VECTOR FOR FIV$220,500
R21 · FY2000 · AI
CYTOKINE RESPONSE IN FIV AND SIV IMMUNODEFICIENCY$96,080
K02 · FY2000 · AI
CHARACTERIZATION/MODULATION OF CYTOKINE RESPONSES IN FIV$81,125
R29 · FY2000 · AI